MOLNMOLECULAR PARTNERS AG

Nasdaq molecularpartners.com


$ 3.67 $ 0.00 (0 %)    

Thursday, 18-Apr-2024 15:59:51 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 3.88
$ 3.67
$ 0.00 x 0
$ 4.15 x 300
$ 3.67 - $ 3.67
$ 3.32 - $ 7.32
254
na
141.05M
$ 0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 molecular-partners-fy-2023-gaap-eps-213-misses-200-estimate-sales-7894m-beat-5333m-estimate

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(2.13) per share which missed the analyst consensus estimate of ...

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

 molecular-partners-ag-says-class-action-complaint-against-company-has-been-dismissed-in-cos-favor

- Reuters

 molecular-partners-presented-initial-data-from-first-four-dosing-cohorts-of-ongoing-phase-12a-trial-of-mp0533-for-patients-with-relapsedrefractory-aml-and-amlmds-at-2023-ash--meeting

Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protei...

 jp-morgan-maintains-neutral-on-molecular-partners-lowers-price-target-to-45

JP Morgan analyst Richard Vosser maintains Molecular Partners (NASDAQ:MOLN) with a Neutral and lowers the price target from ...

 molecular-partners-presents-updated-data-from-ongoing-phase-1-trial-of-mp0317-monotherapy-in-patients-with-advanced-solid-tumors-at-the-2023-sitc-annual-meeting

MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironm...

 molecular-partners-to-present-initial-data-from-ongoing-phase-12a-trial-of-mp0533-for-patients-with-relapsedrefractory-aml-and-amlmds-at-the-65th-ash-annual-meeting-and-exposition

As of data cut-off (20 July 2023) of the abstract published today, five patients across three dosing regimens had been treated....

 molecular-partners-announces-interim-management-statement-for-q3-2023

MP0317 Phase 1 dose escalation recruitment completed in patients with advanced solid tumors; updated clinical results to be pre...

 stocks-that-hit-52-week-lows-on-thursday

  On Thursday, 283 companies set new 52-week lows.

 correction-molecular-partners-h1-eps-105-down-from-486-yoy-sales-385m-down-from-19555m-yoy

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(1.05) per share. This is a 121.6 percent decrease over earnings...

 molecular-partners-h1-eps-105-down-from-486-yoy-sales-385m-down-from-19555m-yoy

Molecular Partners (NASDAQ: MOLN) reported quarterly losses of $(1.05) per share. This is a 121.6 percent decrease over earning...

 earnings-scheduled-for-march-9-2023

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.

 reported-late-monday-molecular-partners-presents-new-preclinical-data-supporting-its-mp0533-darpin-t-cell-engager-for-the-treatment-of-aml

New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagers   Tri...

 molecular-partners-presents-interim-safety-and-mechanistic-data-from-ongoing-phase-1-trial-of-mp0317-for-treatment-of-solid-tumors

First clinical observation of tumor localized CD40 activation provided by MP0317 No systemic or dose-limiting toxicities obs...

 12-health-care-stocks-moving-in-mondays-pre-market-session

Gainers NeuroMetrix (NASDAQ:NURO) shares increased by 23.0% to $3.48 during Monday's pre-market session. The company'...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION